Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Draadje OT, bijzaken & geleuter in de marge!
Volgen
Gene Therapy Comes of Age. The Promise of Immuno-Oncology www.genengnews.com/gen-articles/magaz... Keeping Tabs On Gene Therapy? Big Pharma Is Closing In www.clinicalleader.com/doc/keeping-ta... Koekje erbij.... WO2015061665) JAK1 SELECTIVE INHIBITOR AND USES THEREOF . Applicants: ABBVIE INC. [US/US]; 1 North Waukegan Road North Chicago, IL 60064 (US) Inventors: VOSS, Jeffrey, W.; (US). CAMP, Heidi, S.; (US). PADLEY, Robert, J.; (US) EN)The invention relates to the use of a JAKl kinase- selective inhibitor that has minimal inhibitory activity towards Jak2 kinase for treating a disease, such as an inflammatory disease (e.g., moderate to severe Rheumatoid Arthritis) and/or bone loss, either alone or in combination with a DMARD (disease modifying anti-rheumatic drug), such as methotrexate. The invention also provides pharmaceutical composition, dosage formulation, administration route, and dosage schedule thereof.patentscope.wipo.int/search/en/detail... patentscope.wipo.int/search/en/result...
flosz schreef op 14 mei 2015 00:37 :
Gene Therapy Comes of Age. The Promise of Immuno-Oncology
www.genengnews.com/gen-articles/magaz... Keeping Tabs On Gene Therapy? Big Pharma Is Closing In
www.clinicalleader.com/doc/keeping-ta... Koekje erbij....
WO2015061665) JAK1 SELECTIVE INHIBITOR AND USES THEREOF .
Applicants: ABBVIE INC. [US/US]; 1 North Waukegan Road North Chicago, IL 60064 (US)
Inventors: VOSS, Jeffrey, W.; (US).
CAMP, Heidi, S.; (US).
PADLEY, Robert, J.; (US)
EN)The invention relates to the use of a JAKl kinase- selective inhibitor that has minimal inhibitory activity towards Jak2 kinase for treating a disease, such as an inflammatory disease (e.g., moderate to severe Rheumatoid Arthritis) and/or bone loss, either alone or in combination with a DMARD (disease modifying anti-rheumatic drug), such as methotrexate. The invention also provides pharmaceutical composition, dosage formulation, administration route, and dosage schedule thereof.
patentscope.wipo.int/search/en/detail... patentscope.wipo.int/search/en/result... Goed gevonden flosz. Hier heb je tenminste wat aan!
Pfizer begint wellicht ook te beseffen dat Xeljanz geen toekomst heeft en werkt ook aan selectieve JAK-1 inhibitoren. Voorbeeld 2 uit www.google.be/patents/US20140243312?d... zou PF-04965842 voorstellen. PF-04965842 werd al klinisch getest op gezonde vrijwilligers ( www.clinicaltrials.gov/ct2/results?te... ). Afwachten of Pfizer er brood in ziet in RA.
#CysticFibrosis player: CFTR stabilizer $VRTX $GLPG $PRQR t.co/ZngCZq4c0d
Casht familie Adri Strating miljoenen met beursgang van Galapagos? Biotechparel Galapagos verwacht $275 miljoen op te halen met zijn beursgang op de Nasdaq in New York. Dat maakte het, biotechnologiebedrijf donderdagochtend bekend. Aandeelhouders in het succesverhaal zijn onder meer de erven van superbelegger Adri Strating. De Nederlandse biotech gloeit. Deze week investeerde Pfizer dik $83 miljoen in biostartup AM Pharma. Mogelijk levert de investering nog eens $500 miljoen op als AM Pharma een medicijn tegen nierfalen oplevert. Galapagos, een andere Nederlandse parel, wil $275 miljoen ophalen met een emissie op de biotechbeurs van de Nasdaq. Galapagos, dat werkt aan de ontwikkeling van anti-reumamedicijn Filgotinib, is een biotechstartup waar - anders dan bij AM Pharma - nog wel Nederlandse aandeelhouders in participeren. Familie van Herk, die ooit al in Pharming en Crucell stapte, bezit 8% in het biotechbedrijf. In het aandeelhoudersregister treffen we verder ook Delta Lloyd, Crucell en (opvallend) twee BV's aan van de in 2012 overleden Adri Strating, ooit roemrucht aandeelhouder in Ajax en semi-conductor bedrijf Besi. Volgens het register stapte de voormalige beurshandelaar in 2010 in met T.W.E. Beheer BV en met Gestion BV. De twee vennootschappen, die nu staan geregisteerd op de Minervalaan 103, vertegenwoordigden toen samen een belang van 5,2%. Wie even snuffelt in de jaarverslagen van T.B.W. Beheer Holding kan niet anders dan constateren dat de erfenis van Strating, ooit een gevallen beursman, goed gevuld is. De effectenrekening pluste in 2013 met maar liefst 10% tot € 42 miljoen. Aan financiële activa ronkt er nog eens $108 miljoen op de balans. Galapagos staat er verder prima voor, blijkt uit recente jaarcijfers. Het bedrijf maakte over 2014 een nettowinst van €33 miljoen op een omzet van €108 miljoen. Volgens Galapagos is er nog tot eind 2016 geld in kas om medicijnen te testen. Eind 2014 was er nog €198 miljoen beschikbaar. Tijd om eens uit te stappen. In maart halveerde T.W.E. Beheer ook al de helft van het belang in Besi.www.quotenet.nl/Nieuws/Casht-familie-...
Galapagos Drug in Partnership With AbbVie Looks to Replace HUMIRA Galapagos (GLPG) is the latest biotech stock to list on the Nasdaq Market with an impressive first day of trading as the stock traded up 20%. AbbVie (ABBV) and Johnson & Johnson (JNJ) are set to purchase a sizable slice of the offering as both companies have an interest about the long term visibility of their respective rheumatoid arthritis (RA) franchises. Filgotinib is an RA drug discovered by Galapagos, and in partnership with AbbVie, they are looking to replace the world’s largest selling drug HUMIRA when it goes off-patent. CEO Onno van de Stolpe tells TheStreet's Jill Malandrino GLPG attract a better valuation and increased liquidity with its NASDAQ listing.www.thestreet.com/video/13152416/gala...
Jefferies: GLPG Focus on Significant Upcoming Headline '634 Readouts The critical Phase IIb '634 headline arthritis data are due mid-Apr & early-May for an opt-in decision by partner AbbVie around late-Sep after final results. We see attractive risk-reward based on earlier clinical data, ABBV's desire to own a portfolio of immunology assets, and our '634 NPV. Possible incremental outlicensing deals and the valuable cystic fibrosis alliance, also with ABBV, could provide upside. Our PT rises 21% to €29/share mostly on USD/EUR. GLGP0634 still the main value driver: We are encouraged by the dose-response, magnitude of effect, and absence of safety issues for '634 in the two four-week Phase IIa trials, supporting our $2.5bn WW peak sales, of which $2.2bn is in RA, after launch by YE18E. Headline 12-week data from the RA Phase IIb (Darwin) trials are due in mid-April and early- May for final 24-week results in July, then triggering AbbVie's decision late-September to opt-in paying Galapagos $200m, plus $50m a few months later if the Phase II Crohn's trial is positive too. A 40% risk adjustment yields a c.€22/share NPV. We acknowledge AbbVie's own JAK-1 inhibitor ABT-494 potentially offers the pharma better economics, with its albeit smaller Phase II dose-finding trials likely to read-out by 4Q15E (RA) and mid-18E (CD). We are skeptical as to the extent to which AbbVie is "obligated" to opt-in if defined criteria are met for '634, but nevertheless see attractive risk-reward from the current share price particularly given its management's desire to build a leading portfolio of immunology assets (anti-IL-6R, anti-CD4, etc). FX boost to NPVs: Given the AbbVie '634 and cystic fibrosis deals are USD-denominated, recent EUR weakness increases our NPVs, potentially narrowing future losses. YE14 cash beat our estimate, more than offsetting likely higher 2015E R&D spend. Cystic fibrosis momentum: We are encouraged by progress in the AbbVie CF alliance, with a second corrector candidate to be chosen 2Q, and Phase I data from potentiator GLPG1837 in 3Q15E. The commercially important triple combination could enter Phase II by 1H17E, with '1837 also likely to be developed in Phase II alone for the niche G551D patient population. Valuation/Risks Our €29 Price Target is based on a sum-of-the-parts valuation largely comprising a 40% probability-adjusted NPV for GLPG0634, plus Net Cash. Risks include: (1) efficacy, safety, or regulatory setbacks for '634; (2) need to execute future out-licensing and alliances; and (3) clinical trial failures. Read more: bridgetunnelinvestor.freeforums.net/t... (09-03-15)
Das wel een beetje een achterhaald en oud artikel, Flosz. Maar toch bedankt voor het plaatsen.
Geleuter idd.! Met datum, dat is dan gelijk duidelijk. Is weer eens wat anders t.o.v. centje erbij, centje eraf.
Ik blijf het eigenaardig vinden dat Incyte geen brood gezien heeft in INCB39110/RA. www.google.be/url?sa=t&rct=j&... ,d.bGg Mogelijke verklaringen zijn de focus van Incyte op oncologie en een groot vertrouwen in baricitinib
Early comparison of JAK inhibitors in RA t.co/ofLxOfSurq $INCY $GLPG $PFE via Ozgur Ogut twitter.com/ogut_ozgur JAK Inhibitors for Rheumatoid Arthritis May 16, 2015 With Pfizer's Xeljanz (tofacitinib) already on the market for rheumatoid arthritis (RA), two investigational JAK inhibitors, baricitinib (JAK1/2 inhibitor) and filgotinib (selective JAK1 inhibitor), are in late stage development. With larger datasets slowly emerging, this post will be a placeholder to provide updated data and, within reason, head-to-head comparisons. RA-BUILD VERSUS DARWIN 1 These two trials are in moderate to severe RA patients who continue on their background conventional disease modifying anti-rheumatic drug (cDMARD) in addition to the investigational drug. Both exclude prior use of biologic DMARDs (bDMARD), namely anti-TNF drugs such as adalimumab. Provided below are some relevant trial inclusion and exclusion criteria to better understand the comparison: RA-Build (Baricitinib sponsored by Incyte / Eli Lilly) Inclusion Criteria Have a diagnosis of adult-onset RA as defined by the American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) 2010 Criteria for the Classification of RA Have moderately to severely active RA defined as the presence of at least 6/68 tender joints and at least 6/66 swollen joints Have a C-reactive protein (CRP) or high-sensitivity C-reactive protein (hsCRP) measurement =1.2 times the upper limit of normal (ULN) Have had an insufficient response or are intolerant to cDMARDs and either: Have had regular use of a cDMARD for at least the 12 weeks prior to study entry with a continuous, nonchanging dose for at least 8 weeks prior to study entry For participants not receiving a cDMARD at the time of entry, the investigator will document in the participant's history that the participant had failed, was unable to tolerate, or had a contraindication to treatment with a cDMARD Exclusion Criteria Are currently receiving corticosteroids at doses >10 mg per day of prednisone (or equivalent) or have been receiving an unstable dosing regimen of corticosteroids within 2 weeks of study entry or within 6 weeks of planned randomization Have started treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or have been receiving an unstable dosing regimen of NSAIDs within 2 weeks of study entry or within 6 weeks of planned randomization Are currently receiving concomitant treatment with methotrexate (MTX), hydroxychloroquine, and sulfasalazine or combination of any 3 cDMARDs Have ever received any biologic DMARD DARWIN 1 (Filgotinib sponsored by Galapagos) Inclusion Criteria have a diagnosis of RA since at least 6 months and meeting the 2010 ACR/EULAR criteria of RA and ACR functional class I-III have =6 swollen joints (from a 66 joint count) and =8 tender joints (from a 68 joint count) at Screening and at Baseline Screening serum CRP =0.7 time ULN have received MTX for =6 months and have been on a stable dose (15 to 25 mg/week) of MTX for at least 4 weeks prior to Screening and willing to continue on their current regimen for the duration of the study. Stable doses of MTX as low as 10 mg/week are allowed when there is documented evidence of intolerance or safety issues at higher doses. Exclusion Criteria current therapy with any DMARD other than MTX current or previous RA treatment with a biologic DMARD, with the exception of biologic DMARDs administered in a single clinical study setting more than 6 months prior to Screening (12 months for rituximab or other B cell depleting agents), where the biologic DMARD was effective, and if discontinued, this should not be due to lack of efficacy previous treatment at any time with a cytotoxic agent, other than MTX, before Screening. Below are summarized the 12 week data from RA-Build and DARWIN1, focusing only on the percentage of patients meeting the ACR20, 50 and 70 endpoints. The first two bar graphs include the placebo arm in the respective trials, whereas the third graph compares both datasets with their placebo groups subtracted. The method is an inexact comparison, but is provided as a best approximation for head-to-head comparison. Although once daily and twice daily doses of filgotinib were tested, the two best twice daily doses are plotted. This is in part to simplify the presentation, while being mindful that the twice daily dosing appeared to provide qualitatively improved results for filgotinib. Included in this plot is a best comparison to the percentages achieved by the recommended dose of tofacitinib in Study IV of the tofacitinib registration package.
plaatje bij de posting van flosz
De filgotinib ACR50 kolom is torenhoog, beklimmen zonder ervaring is af te raden. Naar beneden kijkend vanaf de filgotinib ACR kolommen zie je slechts de kopjes van de concurrenten, waarschijnlijk al in nevel verhuld.
stappa schreef op 16 mei 2015 20:04 :
De filgotinib ACR50 kolom is torenhoog, beklimmen zonder ervaring is af te raden. Naar beneden kijkend vanaf de filgotinib ACR kolommen zie je slechts de kopjes van de concurrenten, waarschijnlijk al in nevel verhuld.
Zoals Ozgur Ogut zelf al aangeeft (“The method is an inexact comparison, but is provided as a best approximation for head-to-head comparison. Although once daily and twice daily doses of filgotinib were tested, the two best twice daily doses are plotted. This is in part to simplify the presentation, while being mindful that the twice daily dosing appeared to provide qualitatively improved results for filgotinib.”) is de vergelijking niet echt waterdicht zolang er geen head-to-head studies gebeuren. Vergelijk de once-daily data van beide producten en je hoeft echt niet ver meer naar beneden te kijken. Mijn buikgevoel zegt me ook wel dat filgotinib een wat betere werking vertoont dan baricitinib maar Eli Lilly gaat wellicht 2 jaar de tijd hebben om zijn deel van de koek op te eisen door te stellen dat baricitinib minder nevenwerkingen heeft dan Xeljanz. En als filgotinib dan op de markt zou komen kan Eli Lilly de nadruk leggen op het once-daily aspect van baricitinib.
Die once en twice dosing discussie is een interessante waar ik nog weinig over kan vinden. De resultaten voor 2 x 100 mg waren beter dan 1 x 200 mg. Toch meen ik gelezen te hebben dat men verder wil gaan met 1 x 200 mg. Klopt dat? En wat zou daar de reden voor kunnen zijn? Gebruiksgemak boven werkzaamheid?
Die eerste is inderdaad het topic dat daar over gaat, maar daar komt niet duidelijk uit naar voren waarom er met 200 mg verder gegaan wordt. Die tweede stuurt me niet naar een pagina met een post van Maxen. Anyway, ik wacht het af. Wellicht dat de 24-weeks resultaten hier meer duidelijkheid over geven. Thanks!
De eenmaal daagse monotherapie in de DARWIN 2 studie leidde tot een gelijkaardige werkzaamheid als werd gezien bij de hoge doses in DARWIN 1, waar patiënten werden behandeld met een één- of tweemaal daagse dosis filgotinib gecombineerd met methotrexaat.(Dr Piet Wigerinck)
So remarkable within one week patients of all dose groups report a statistical significant difference from placebo. At week 12, patients of all groups have reported at least 25-point drop measured as a mean, a very solid improvement of their disease and all groups easily reach a statistical significance here. So let there be no doubt, when we initiate treatment to filgotinib of the once a day and even as a monotherapy, patients and physicians observe and report improvements from the first week onwards, a clear proof of the fast onset of action. www.glpg.com/files/4314/3037/7975/GLP... p.5
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
AIRBUS
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
Nextensa
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia Oyj
Nokia OYJ
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)